Common questions about Crysvita (FAQ)
Q: Is Crysvita a cure for my condition?
Crysvita is approved for the treatment of X-linked hypophosphatemia (XLH) and Tumor-induced osteomalacia (TIO). It is a targeted, disease-modifying therapy that addresses the underlying metabolic cause of the condition by supporting bone mineralization. Official information does not describe the medicine as a cure.
Q: How quickly should I expect to see results after starting Crysvita?
Clinical studies show that monitoring of key biochemical markers, such as blood phosphate levels, was assessed beginning at two weeks after the first dose. Adjustments to the dosage schedule are guided by these levels after a period of treatment, typically starting after the first month. Improvements in skeletal parameters are evaluated over longer periods, often between 40 to 64 weeks.
Q: What happens if I miss a dose of Crysvita?
Regulatory guidelines state that treatment with Crysvita should be resumed as soon as possible if a dose is missed.
Q: Why is Crysvita given as an injection instead of a pill?
Crysvita is a biologic medicine, specifically a recombinant monoclonal antibody. Biologics are typically given by injection to avoid the digestive system breaking down the active ingredient, which ensures the medicine remains effective in the body.
Q: Is it normal to feel tired after a Crysvita injection?
While tiredness (fatigue) is a reported symptom of the underlying condition (XLH), it is not listed among the most common adverse reactions reported in the drug's regulatory label. However, headache and pain in extremity are classified as common side effects.
Q: Are there any long-term risks associated with Crysvita treatment?
The official product information documents the potential for serious adverse reactions, including serious hypersensitivity reactions. The label also notes a documented risk of nephrocalcinosis (mineral deposits in the kidneys), which has been associated with persistent elevated phosphate levels.
Q: Does Crysvita help with bone pain?
Clinical studies monitored patient-reported outcomes for symptoms like joint stiffness and pain intensity in adults with XLH. Findings related to these outcomes were observed in the populations studied.
Q: Is there a generic version of Crysvita available?
Crysvita is the brand name for the specialized biologic drug burosumab-twza. Biologic medicines do not have generic versions; instead, they may have biosimilar products, but no biosimilar is currently approved or listed for this drug substance.
Q: What kind of specialist typically prescribes Crysvita?
Official information indicates that this medicine is generally prescribed by, or in consultation with, a specialist experienced in diagnosing and treating metabolic bone disorders.
Q: Can I travel while on a Crysvita treatment schedule?
Travel is possible, but Crysvita must be stored and handled according to the specific temperature requirements listed in the official product information. It must be kept refrigerated at the required temperature range to maintain stability. If an injection is missed, regulatory guidelines indicate it should be administered as soon as possible thereafter.
Q: How long does it take for the injection site reaction from Crysvita to go away?
Injection site reactions, such as swelling, redness, or pain, were reported in clinical trials. These reactions were generally described as mild in intensity and typically resolved within 1 to 3 days.
Q: Are there any reported cases of serious side effects with Crysvita?
The official product information documents the potential for serious adverse reactions. These include the risk of serious hypersensitivity reactions and the documented risk of nephrocalcinosis, which involves mineral deposits in the kidneys.
Q: Is Crysvita used to treat other bone disorders besides XLH?
In addition to X-linked hypophosphatemia (XLH), the medicine is also approved for the treatment of Tumor-Induced Osteomalacia (TIO). This indication applies to TIO patients whose tumors cannot be curatively resected or localized.
Q: What are the signs of having too much or too little phosphate while on Crysvita?
Official drug labels do not list common symptoms of high or low phosphate. Regular monitoring of fasting serum phosphorus levels is required to ensure that levels remain within the normal range and to guide appropriate dose adjustments.
Q: Can people with kidney stones use Crysvita?
Crysvita is contraindicated (prohibited) for patients with severe renal impairment or end-stage renal disease. The medicine also carries a documented risk of nephrocalcinosis (mineral deposits in the kidneys), which is associated with persistent elevated phosphate levels.
Q: What is the success rate of Crysvita in clinical studies?
Clinical trials describe the medicine’s outcomes based on several objective markers rather than a single 'success rate.' For example, studies in children reported a high percentage of patients achieving a reduction in the radiographic severity of rickets.
Q: Can Crysvita improve walking ability or mobility?
Clinical trials measured skeletal and biochemical markers intended to support bone health and integrity. The official label notes that patient-reported outcomes for joint stiffness and pain intensity were monitored in these studies.
Q: Can Crysvita be administered at home?
Regulatory documents state that Crysvita must be administered by a qualified healthcare professional. The official label does not specify the exact location of administration, only the requirement for professional supervision.
Q: What percentage of people experience injection site reactions with Crysvita?
According to the official product information, injection site reactions are classified as Very Common. This means they were reported to occur in 1 out of every 10 patients or more in clinical trials.
Q: What scientific breakthrough led to the development of Crysvita?
Crysvita is a targeted therapy developed to address the underlying cause of certain metabolic bone disorders. It works by inhibiting Fibroblast Growth Factor 23 (FGF23), a hormone that regulates phosphate balance.
Q: How is the long-term safety of Crysvita monitored?
Clinical development included long-term, open-label extension studies. These studies track patient responses and monitor symptom patterns over several years to gather extended information on safety and effectiveness.
Q: Does Crysvita improve quality of life for patients with XLH?
Clinical trials monitored patient-reported outcomes for key indicators. This included tracking changes in joint stiffness and pain intensity experienced by patients.
Q: Can I take vitamin D supplements while receiving Crysvita?
Official information states that Crysvita should not be used concurrently with oral phosphate supplements and/or active vitamin D analogs (such as calcitriol or alfacalcidol). The FDA label does state that doctors may supplement with forms like cholecalciferol or ergocalciferol if needed to maintain appropriate vitamin D levels.
Q: How long does the effect of one Crysvita dose last?
Crysvita is administered on a fixed schedule (every two or four weeks) and is intended for long-term use. Serum phosphate levels are monitored regularly to help ensure they remain in the target range before the next scheduled dose.
Q: Why is my doctor checking my phosphorus levels so often while on Crysvita?
Fasting serum phosphorus levels must be monitored regularly, as required by the regulatory label. This monitoring is done to ensure phosphate levels are maintained within the normal reference range for the patient's age and to guide any necessary adjustments to the dosage.
Q: Does Crysvita affect dental health?
Official regulatory lists of adverse reactions note that events such as tooth infection, dental cavities, and tooth abscess were reported during clinical trials in both children and adults.
